Navigation Links
ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb
Date:10/30/2010

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced the ANA598 data to be presented at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston, MA.  ANA598, the Company's direct-acting antiviral (DAA) being developed for the treatment of hepatitis C, will be discussed in two presentations at the conference:  

  • On Sunday, October 31, 2010 at 3:00 pm Eastern Daylight Time, Eric Lawitz, M.D., a principal investigator of the study, will give an oral presentation titled, "Safety and Antiviral Activity of ANA598 in Combination with Pegylated Interferon alpha 2A Plus Ribavirin in Treatment-Naive Genotype-1 Chronic HCV Patients."  The slides will be available on the Company's website at www.anadyspharma.com following conclusion of the presentation.  
  • On Tuesday, November 2, 2010 at 7:00 am Eastern Daylight Time, Anadys will present data in a poster titled, "IL28B Polymorphism and Kinetics of Antiviral Activity for ANA598 in Combination with Pegylated Interferon alpha 2A Plus Ribavirin in Treatment-Naive Genotype-1 Chronic HCV Patients."  The poster will be available on the Company's website at www.anadyspharma.com.  

"We are pleased with the positive clinical profile seen to date for ANA598, as well as its preclinical properties that support investigation of combinations with other direct antivirals," said James L. Freddo, M.D., Senior Vice President, Drug Development and Chief Medical Officer of Anadys.  "In the upcoming Phase IIb study, we look forward to testing ANA598 for the first time in treatment-experienced patients, as well as in a larger population of treatment-naive patients."

In the oral pr
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
11. ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Taskforce representing Canada,s living victims of ... the Minister and Health Canada have put into this program ... of the thalidomide survivors, and more than 70% of them ... annual adjustments for inflation. Certain of the thalidomide ... on the severity of their disability, tax free, with inflation ...
(Date:5/22/2015)... HILL, N.C. , May 22, 2015 /PRNewswire/ ... critical to pharmaceutical brand recognition and success. ... LLC conducted a study to provide pharmaceutical and ... of investment (FTEs and budget) that are being ... Pharmaceutical and biotech marketing managers can utilize this ...
(Date:5/22/2015)... , May 22, 2015 The leading ... $13 billion global cardiac rhythm management device market ... found that Medtronic, St. Jude Medical, Boston Scientific ... of this market segment. The healthcare market research ... , uses 2015 as a base year, providing ...
Breaking Medicine Technology:Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4
(Date:5/23/2015)... With the implementation of the Affordable Care ... difficult to provide their employees with a viable healthcare ... for employees stand to face strict penalties. Never before ... of a business’s success or failure. In an effort ... Doctors has created a varying level of less expensive ...
(Date:5/23/2015)... A live auction will be held to sell over ... other medical facilities around the United States. Various types ... anesthesia, exam and much more. , The live auction ... starting at 9:00am CDT each day. The equipment is at ... Park, IL 60160. Anyone can participate in the auction ...
(Date:5/22/2015)... The world is at a ... intersecting to create new opportunities for leadership in ... at WesternU's 34th annual Commencement Exercises said Wednesday, ... a former San Francisco mayor and likely 2018 ... graduation ceremony for WesternU's colleges of Allied Health ...
(Date:5/22/2015)... River Valley Health Partners (RVHP) Board ... system’s Chief Financial Officer (CFO), will be leaving the ... the company CFO since 2011. , The Board of ... health system as CFO. Wesley will oversee the health ... Board of Trustees conducts a formal search for a ...
(Date:5/22/2015)... UK (PRWEB) May 22, 2015 ... leading treatment option for chronic obstructive pulmonary disorder ... GlaxoSmithKline plc and AstraZeneca plc as well as ... market share and position. But will market payers, ... the already well-entrenched products to completely new ones? ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2
... , SUNDAY, May 13 (HealthDay News) -- A new type ... people who have lost their vision due to degenerative eye ... research with rats. The system uses tiny solar panel-like ... a specially designed pair of goggles equipped with a miniature ...
... new study has found that, contrary to current thinking, taking ... a person,s risk of developing colorectal cancer. Published early online ... Cancer Society, the study also revealed that even long-term use ... cancer risk. In recent years, researchers have thought that ...
... , THURSDAY, May 10 (HealthDay News) -- An advisory panel ... approval of the weight-loss medication lorcaserin, even though concerns remain ... give the nod to the drug, lorcaserin would become the ... decade. The FDA is not bound to follow the advice ...
... is the leading cause of death among children under 5, ... Johns Hopkins Bloomberg School of Public Health. They examined the ... found that 64 percent were attributable to infectious causes and ... the May issue of the Lancet , suggest a ...
... who are making a big difference in the highly ... two early-stage discovery awards from Grand Challenges Explorations, an ... The global health projects will focus on creating ... for low-cost, in-home diagnoses. The prestigious awards ...
... reduced mobility now have access to specialized exercise equipment ... between the University of Alberta and the Spinal Cord ... functional electrical stimulation (FES) rehabilitation therapy machines are now ... the Faculty of Physical Education and Recreation at the ...
Cached Medicine News:Health News:In Rat Study, Eye Device Shows Promise for Restoring Sight 2Health News:Blood pressure drugs don't protect against colorectal cancer 2Health News:FDA Panel Gives Blessing to New Weight-Loss Drug 2Health News:Pneumonia and preterm birth complications are the leading causes of childhood death 2Health News:2 Grand Challenges Explorations grants for global health 2Health News:Partnership provides inclusive workout 2Health News:Partnership provides inclusive workout 3
... The assay is a direct competitive ... in human serum or plasma. A specific ... it available for antibody binding. Estradiol then ... to fluorescein isothiocyanate (FITC) and alkaline phosphatase ...
... the most potent, naturally secreted estrogen and ... ovary [1]. In the ovary, estradiol is ... a less potent estrogen derived from androstenedione. ... body tissues. In men, small amounts of ...
... troponin I (cTnI) has been useful in ... Emergency Departments (ED) with chest pain. 18-20 ... when blood levels of sensitive and specific ... isoenzyme of creatine kinase (CK-MB), and myoglobin, ...
The second-generation Dade Behring Acute Care Troponin I (cTnI) method is the first FDA cleared high sensitivity cTnI assay with the low-end precision necessary to meet the ESC/ACC guidelines (CV <10...
Medicine Products: